Abstract: It is an aspect of the present invention to provide a method for recording a response to Transcranial Magnetic Stimulation (TMS) utilizing a bi-phasic double pulse pair from a TMS coil device to stimulate a subject wherein the second pulse has a lower amplitude compared to the first pulse in the bi-phasic double pulse pair. Significant advantages are achieved using bi-phasic double pulse pairs, particularly where the second pulse in a pair has an intensity lower than the first. Obtaining measurements is simpler and more accurate as the number and intensity of stimulation can be reduced compared to standard single pulse stimulation.

Abstract: It is an aspect of the present invention to provide a method for recording a response to Transcranial Magnetic Stimulation (TMS) utilizing a bi-phasic double pulse pair from a TMS coil device to stimulate a subject wherein the second pulse has a lower amplitude compared to the first pulse in the bi-phasic double pulse pair. Significant advantages are achieved using bi-phasic double pulse pairs, particularly where the second pulse in a pair has an intensity lower than the first. Obtaining measurements is simpler and more accurate as the number and intensity of stimulation can be reduced compared to standard single pulse stimulation.

Abstract: It is an aspect of the present invention to provide a method for recording a response to Transcranial Magnetic Stimulation (TMS) utilizing a bi-phasic double pulse pair from a TMS coil device to stimulate a subject wherein the second pulse has a lower amplitude compared to the first pulse in the bi-phasic double pulse pair. Significant advantages are achieved using bi-phasic double pulse pairs, particularly where the second pulse in a pair has an intensity lower than the first. Obtaining measurements is simpler and more accurate as the number and intensity of stimulation can be reduced compared to standard single pulse stimulation.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.

Abstract: It is an aspect of the present invention to provide a method for recording a response to Transcranial Magnetic Stimulation (TMS) utilizing a bi-phasic double pulse pair from a TMS coil device to stimulate a subject wherein the second pulse has a lower amplitude compared to the first pulse in the bi-phasic double pulse pair. Significant advantages are achieved using bi-phasic double pulse pairs, particularly where the second pulse in a pair has an intensity lower than the first. Obtaining measurements is simpler and more accurate as the number and intensity of stimulation can be reduced compared to standard single pulse stimulation.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.

Abstract: The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAc?3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: Provided is a method for protecting stem cells in a clinical graft against destruction induced by the complement system by adding to the graft at least one factor capable of inhibiting the complement. Also provided is a method for protecting stem cells in a clinical graft against destruction induced by the complement system using a factor capable of inhibiting the complement.

Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.

Abstract: The present invention provides methods and materials to modulate and grow stem cells by contacting stem cells with a binder recognizing terminal glycan structures of stem cells. The modulation can be morphological change, change in differentiation status, biological status or adherence. The materials provided in the present invention are also useful to screen such a binding agents and binders.

Abstract: The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.

Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by changing sialylation and/or fucosylation levels of the cells. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered. The control methods are preferably mass spectrometric methods.

Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.